Targets › SIRPA
6 programs from 5 companies in 11 trials: 10 Phase 1, 1 Phase 2; Oncology, Hematology; next expected readout Dec 2026.
Immunoglobulin-like cell surface receptor for CD47. Acts as docking protein and induces translocation of PTPN6, PTPN11 and other binding partners from the cytosol to the plasma membrane. (UniProt, P78324)
Open in Phaseline: the race on SIRPA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Electra Therapeutics | ELA026 SIRP-directed monoclonal antibody | SIRPA | Phase 2 | Secondary Hemophagocytic Lymphohistiocytosis (sHLH); T Cell Malignancies | Mar 2028 |
| Byondis | Rituximab (BYON4228) B-lymphocyte antigen CD20 binding agent | MS4A1, SIRPA | Phase 1 | Lymphoma; Solid Tumor | Dec 2026 |
| FBD Biologics | HCB301 Engineered SIRPα fused to anti-PD-L1 and TGF-β fusion protein | SIRPA, PDCD1LG2, TGFB1 | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| Sairopa | ADU-1805 anti-SIRPα monoclonal antibody | SIRPA | Phase 1 | Solid Tumor, Adult | May 2027 |
| FBD Biologics | HCB101 SIRPα-Fc fusion protein targeting CD47 | SIRPA, CD47 | Phase 1 | Advanced Solid Tumor; Solid Cancer; CRC; HNSCC | May 2027 |
| Kahr Medical | DSP107 SIRPα-4-1BBL bi-functional fusion protein; engages SIRPα on macrophages (CD172a) to block | SIRPA, TNF | Phase 1 | Advanced Solid Tumor | – |
Advanced Solid Tumor (3) Solid Tumor, Adult (1) Secondary Hemophagocytic Lymphohistiocytosis (sHLH) (1) T Cell Malignancies (1) Solid Cancer (1) CRC (1) HNSCC (1) Lymphoma (1) Solid Tumor (1)
mixed (3), small molecule (2), antibody (1)
FBD Biologics (2) Sairopa (1) Electra Therapeutics (1) Kahr Medical (1) Byondis (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.